Compass Therapeutics (CMPX) Return on Capital Employed (2019 - 2026)
Compass Therapeutics recorded quarterly Return on Capital Employed of 37.2% in Q1 2026, down 7.98% quarter-over-quarter from 34.45% in Q4 2025, and up 1389.0% year-over-year from 2.5% in Q1 2025.
Compass Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 37.2% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1389.0% year-over-year to 37.2%; the TTM figure through Mar 2026 stood at 37.2% (up 1389.0% YoY), while the FY2025 annual figure was 43.87%, down 336.0% from the prior year.
- Return on Capital Employed came in at 37.2% for Q1 2026 at Compass Therapeutics, down from 34.45% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 23.7% in Q1 2022 to a low of 61.56% in Q2 2025.
- A 5-year average of 35.55% and a median of 34.44% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 4568 bps in 2022 and sank 2452 bps in 2025, its largest moves.
- Compass Therapeutics' Return on Capital Employed stood at 28.23% in 2022, then declined by 15 bps to 32.36% in 2023, then retreated by 29 bps to 41.67% in 2024, then gained by 17 bps to 34.45% in 2025, then retreated by 8 bps to 37.2% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 37.2%, 34.45%, and 44.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -37.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.20% |
| Dec 31, 2025 | -34.45% |
| Sep 30, 2025 | -44.21% |
| Jun 30, 2025 | -61.56% |
| Mar 31, 2025 | -51.08% |
| Dec 31, 2024 | -41.67% |
| Sep 30, 2024 | -37.48% |
| Jun 30, 2024 | -37.04% |
| Mar 31, 2024 | -34.44% |
| Dec 31, 2023 | -32.36% |
| Sep 30, 2023 | -28.92% |
| Jun 30, 2023 | -27.91% |
| Mar 31, 2023 | -24.19% |
| Dec 31, 2022 | -28.23% |
| Sep 30, 2022 | -33.56% |
| Jun 30, 2022 | -26.43% |
| Mar 31, 2022 | -23.70% |
| Dec 31, 2021 | -42.00% |
| Mar 31, 2021 | -69.38% |
| Sep 30, 2020 | -35.55% |
| Jun 30, 2020 | -81.70% |
| Mar 31, 2020 | -151.83% |
| Dec 31, 2019 | -317.98% |
| Sep 30, 2019 | 19,299.87% |
| Jun 30, 2019 | 10,600.66% |